Janus Henderson Group PLC raised its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 18.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,763,195 shares of the company's stock after acquiring an additional 599,203 shares during the quarter. Janus Henderson Group PLC owned approximately 11.38% of Lexeo Therapeutics worth $33,997,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vestal Point Capital LP lifted its position in shares of Lexeo Therapeutics by 1.2% during the 3rd quarter. Vestal Point Capital LP now owns 850,000 shares of the company's stock worth $7,684,000 after purchasing an additional 10,000 shares during the last quarter. Verition Fund Management LLC raised its stake in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company's stock valued at $7,027,000 after buying an additional 355,928 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Lexeo Therapeutics by 15.8% during the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company's stock worth $7,554,000 after buying an additional 65,573 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Lexeo Therapeutics by 107.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company's stock worth $577,000 after buying an additional 33,013 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Lexeo Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company's stock worth $510,000 after acquiring an additional 3,483 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company's stock.
In related news, CEO Richard Nolan Townsend sold 5,000 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $10.65, for a total value of $53,250.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at $1,285,401.75. The trade was a 3.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 12,500 shares of company stock worth $113,300. Company insiders own 4.50% of the company's stock.
Several research firms recently weighed in on LXEO. Chardan Capital boosted their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. HC Wainwright upped their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, November 14th. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. Finally, Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $23.80.
Read Our Latest Analysis on Lexeo Therapeutics
Shares of NASDAQ:LXEO opened at $7.63 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The stock has a market cap of $252.32 million and a P/E ratio of -2.41. Lexeo Therapeutics, Inc. has a 1-year low of $5.77 and a 1-year high of $22.33. The firm has a fifty day moving average price of $8.21 and a 200 day moving average price of $11.57.
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.